Glenmede Trust CO Na Arcellx, Inc. Transaction History
Glenmede Trust CO Na
- $20.6 Billion
- Q3 2024
A detailed history of Glenmede Trust CO Na transactions in Arcellx, Inc. stock. As of the latest transaction made, Glenmede Trust CO Na holds 3,615 shares of ACLX stock, worth $350,401. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,615Holding current value
$350,401% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
201Shares Held
44.1MCall Options Held
2.1MPut Options Held
778K-
Paradigm Biocapital Advisors LP New York, NY4MShares$388 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$377 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$363 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$341 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$239 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $4.25B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...